Myriad Genetics, Inc. (MYGN)
| Market Cap | 1.66B |
| Revenue (ttm) | 753.20M |
| Net Income (ttm) | -263.30M |
| Shares Out | 89.87M |
| EPS (ttm) | -3.18 |
| PE Ratio | n/a |
| Forward PE | 632.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 441,847 |
| Open | 18.42 |
| Previous Close | 18.51 |
| Day's Range | 18.24 - 18.69 |
| 52-Week Range | 13.82 - 24.21 |
| Beta | 1.98 |
| Analysts | Buy |
| Price Target | 22.50 (+21.62%) |
| Earnings Date | May 1, 2024 |
About MYGN
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic pros... [Read more]
Financial Performance
In 2023, MYGN's revenue was $753.20 million, an increase of 11.03% compared to the previous year's $678.40 million. Losses were -$263.30 million, 135.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MYGN stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 21.62% from the latest price.
News
Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
80% of people diagnosed with anxiety, depression report losing years or decades of time 80% of people diagnosed with anxiety, depression report losing years or decades of time
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a s...
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight...
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Tradema...
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office...
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
Highlights: Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek ® volume. Full-year 2023 revenue of $753 million , grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek),...
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Myriad's Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad's Precise MRD test will be used to evaluate the broad applicability of MRD tes...
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Management will also participate in two upcoming healthcare conferences Management will also participate in two upcoming healthcare conferences
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG,...
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Inte...
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD,...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement...
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Cl...
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd...
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief F...
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
The Myriad Collaborative Research Registry has more than one million patient cases The Myriad Collaborative Research Registry has more than one million patient cases
Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics, as Strategic Advisor
GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, a leading functional precision oncology company specializing in 3D cell culture technology and delivering evidence of therapeutic response in the oncology s...
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million con...
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis' ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx ...
Myriad Genetics to Participate in Stephens Annual Investment Conference
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the S...
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the pri...
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that it...
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek ® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year growt...
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operat...
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Mon...